Fediuk J, Sikarwar AS, Nolette N, Dakshinamurti S. Thromboxane-induced actin polymerization in hypoxic neonatal pulmonary arterial myocytes involves CDC42 signaling. Am J Physiol Lung Cell Mol Physiol 307: L877-L887, 2014. First published October 3, 2014 doi:10.1152/ajplung.00036.2014.-In hypoxic pulmonary arterial (PA) myocytes, challenge with thromboxane mimetic U46619 induces marked actin polymerization and contraction, phenotypic features of persistent pulmonary hypertension of the newborn (PPHN). Rho GTPases regulate the actin cytoskeleton. We previously reported that U46619-induced actin polymerization in hypoxic PA myocytes occurs independently of the RhoA pathway and hypothesized involvement of the Cdc42 pathway. PA myocytes grown in normoxia or hypoxia for 72 h were stimulated with U46619, then analyzed for Rac/Cdc42 activation by affinity precipitation, phosphatidylinositide-3-kinase (PI3K) activity by phospho-Akt, phospho-p21-activated kinase (PAK) by immunoblot, and association of Cdc42 with neuronal Wiskott Aldrich Syndrome protein (N-WASp) by immunoprecipitation. The effect of Rac or PAK inhibition on filamentous actin was quantified by laser-scanning cytometry and by cytoskeletal fractionation; effects of actin-modifying agents were measured by isometric myography. Basal Cdc42 activity increased in hypoxia, whereas Rac activity decreased. U46619 challenge increased Cdc42 and Rac activity in hypoxic cells, independently of PI3K. Hypoxia increased phospho-PAK, unaltered by U46619. Association of Cdc42 with N-WASp decreased in hypoxia but increased after U46619 exposure. Hypoxia doubled filamentous-to-globular ratios of ␣-and ␥-actin isoforms. Jasplakinolide stabilized ␥-filaments, increasing force; cytochalasin D depolymerized all actin isoforms, decreasing force. Rac and PAK inhibition decreased filamentous actin in tissues although without decrease in force. Rho inhibition decreased myosin phosphorylation and force. Hypoxia induces actin polymerization in PA myocytes, particularly increasing filamentous ␣-and ␥-actin, contributing to U46619-induced contraction. Hypoxic PA myocytes challenged with a thromboxane mimetic polymerize actin via the Cdc42 pathway, reflecting increased Cdc42 association with N-WASp. Mechanisms regulating thromboxane-mediated actin polymerization are potential targets for future PPHN pharmacotherapy. actin polymerization; actin isoforms; persistent pulmonary hypertension of the newborn; hypoxia; thromboxane; Rac; Cdc42 PULMONARY VASCULAR RESISTANCE is high in utero but declines at birth to accommodate increasing pulmonary blood flow (18). This decrease in pulmonary arterial resistance is attributed to dilatation and recruitment of intra-acinar arteries, reduced arterial muscle, growth and remodeling of the pulmonary arteries, increased release of vasodilators, and decreased vasoconstrictors (16). Failure of pulmonary arterial relaxation at birth leads to persistent pulmonary hypertension of the newborn (PPHN), precipitated by perinatal hypoxia, meconium aspiration, sepsis or inflammation (46), resulting in highpressure pulmonary circulation and inadequate oxygen supply to organs (49). PPHN has an incidence of 2-6/1,000 births (52), with mortality attributable to hypoxemia and respiratory failure (36).
birth leads to persistent pulmonary hypertension of the newborn (PPHN), precipitated by perinatal hypoxia, meconium aspiration, sepsis or inflammation (46) , resulting in highpressure pulmonary circulation and inadequate oxygen supply to organs (49) . PPHN has an incidence of 2-6/1,000 births (52) , with mortality attributable to hypoxemia and respiratory failure (36) .
In utero, pulmonary arterial smooth muscle cells (PASMCs) are rounded and densely packed, resulting in a thick arterial wall and narrow lumen (15) . The myocyte actin cytoskeleton undergoes remodeling during circulatory adaptation after birth (21) , as exposure to normoxic conditions promotes actin filament disassembly to permit myocyte elongation. PPHN prevents the transient postnatal reduction in actin content, resulting in highly polymerized actin and increased vasoconstriction (20) . Importantly, a key change in the histology of PPHN pulmonary arteries is increased immunostaining of medial smooth muscle for the ␥-isoform of actin (20) . The functional role of increased ␥-actin in hypoxic pulmonary vasoconstriction in newborns has never been elucidated.
The dynamic polymerization and depolymerization of actin filaments is necessary for smooth muscle contraction and relaxation (23, 31, 47) . Actin cytoskeletal changes also contribute toward loss of mural elastic properties, inward remodeling, and increased wall thickness in hypertensive resistance arteries (4) . Actin polymerization is known to be regulated by activity of receptor-linked small GTPases Rho, Rac, and Cdc42. In a neonatal porcine model of hypoxic PPHN, we previously reported that actin polymerization increases smooth muscle force generation and thereby enhances thromboxanemediated pulmonary arterial constriction (13) . In a matched in vitro model of pulmonary arterial hypoxia, we demonstrated that challenge of hypoxic pulmonary artery myocytes with the thromboxane mimetic U46619 markedly induces actin polymerization. This increase in polymerized actin occurs independently of the RhoA pathway, reflected by decreased thromboxane receptor (TP) association with G␣12/13 in favor of G␣q, diminished activation of RhoA pathway intermediates including LIM-domain kinase (LIMK), and insensitivity of actin polymerization to Rho kinase inhibition (13) . These data suggested to us that, whereas Rho kinase inhibitors have demonstrated potential for acute vasodilation in pulmonary arterial hypertension (5, 27) , Rho pathway inhibition may not address the ancillary problem of cytoskeletal remodeling in hypoxic pulmonary artery. We then sought to examine other related signaling pathways for intervention potential. In context of the historical finding that PPHN pulmonary arteries are distinguished by the persistence of ␥-actin, we also targeted signaling for polymerization of this component of the actin pool. In the present study, we examine the importance of Rac and Cdc42 pathways in regulating thromboxane-induced actin polymerization, in hypoxic pulmonary arterial myocytes after challenge with thromboxane mimetic U46619, and the effects of these pathways on inclusion of ␣-, ␤-, and ␥-actin isoforms in the filamentous fraction of hypoxic myocytes. Actin-stabilizing and -destabilizing agents were used to infer the importance of actin polymerization for the U46619 contractile response. We hypothesized that 1) hypoxia will promote polymerization of actin isoforms-␣ and -␥, contributing to enhanced vasoconstriction; 2) U46619-induced polymerization of actin in hypoxic pulmonary artery myocytes will require the Cdc42 pathway; and 3) inhibition of actin polymerization via this pathway will attenuate the U46619 contractile response in hypoxic myocytes. Determining the mechanism for thromboxane-induced actin polymerization in hypoxic pulmonary artery myocytes may have implications for therapeutic management of pulmonary arterial remodeling in the presence of hypoxia and inflammatory prostanoids in infants with PPHN.
MATERIALS AND METHODS
Reagents. Thromboxane mimetic U46619 and cytochalasin D were purchased from Sigma; Rac1 inhibitor (NSC23766), p21-activated kinase (PAK1) inhibitor (IPA-3), Rho kinase inhibitor (Y27632), and jasplakinolide were from Calbiochem; Rac and Cdc42 activation assays were from Cytoskeleton. The following antibodies were used: polyclonal anti-pan actin (1:1,000; Cytoskeleton), monoclonal ␣-smooth muscle actin (1:10,000; Sigma), monoclonal anti-␤ actin (1:5,000; Sigma), monoclonal ␥-actin (1:1,000; Santa Cruz Biotechnology), PAK1 (1:1,000; Cell Signaling), phospho-PAK1(Thr423)/ PAK2(Thr402) (1:1,000; Cell Signaling), phospho-Akt(Ser473) (1: 1,000; Cell Signaling), Akt Cell culture and in vitro hypoxia. The University of Manitoba Central Animal Care approved all animal care protocols in accordance with the Canadian Council of Animal Care. PASMCs were obtained from newborn piglets (Ͻ24 h old) using a dispersed cell culture method (41) . Second-to sixth-generation pulmonary arteries were recovered in cold HEPES-buffered saline solution (HBS; composition in mM: 130 NaCl, 5 KCl, 1.2 MgCl 2, 1.5 CaCl2, 10 HEPES, 10 glucose; pH 7.4) with antibiotic/antimycotic mixture, washed with Ca 2ϩ -reduced HBS (20 M CaCl2), minced, and digested with type I collagenase (1,750 U/m;), dithiothreitol (1 mM), bovine serum albumin (2 mg/ml), and papain (9.5 U/ml) for 15 min at 37°C. Dispersed cells were collected at 1,200 revolution/min for 5 min, washed, and resuspended in Ham's F-12 medium containing L-glutamine, 10% fetal bovine serum, 1% penicillin, and 1% streptomycin. At ϳ80% confluence, myocytes were serum deprived for 48 h in F-12 media with 1% penicillin/streptomycin and 1% insulin-transferrin-selenium to synchronize cells in a contractile phenotype. PASMCs were then randomized to hypoxic (10% O 2, 5% CO2) or normoxic (21% O2, 5% CO2) conditions for an additional 72 h.
Induction of PPHN. This protocol was approved in accordance with the Canadian Council on Animal Care. To induce PPHN in vivo, newborn piglets (Ͻ24 h old; n ϭ 5) were raised in normobaric hypoxia for 72 h (FI O 2 ϭ 0.10). Age-matched controls were raised in normoxia for 3 days (FIO 2 ϭ 0.21; n ϭ 5). Piglets were euthanized by pentobarbital overdose and exsanguination. Heart and lungs were removed en bloc into oxygenated cold (4°C) Ca 2ϩ -free KrebsHenseleit buffer (containing in mM: 112.6 NaCl, 25 NaHCo 3, 1.38 NaH 2PO4, 4.7 KCl, 2.46 MgSO4·7H20, 5.56 dextrose; pH 7.4). PPHN was confirmed by the presence of cardiac right ventricular hypertrophy (10) . Pulmonary arteries were isolated by microdissection for myography (below).
Stress fiber isolation. Neonatal myocytes were serum deprived as above and exposed to normoxia or hypoxia. Cells were stimulated with 10 Ϫ6 M U46619 (TP agonist; Sigma) or diluent for 30 min in media, then washed with ice-cold PBS with 1 mM MgCl 2. Isolation of stress fibers was adapted from Katoh et al. (22) . Briefly, the soluble cellular components were collected over a series of washes with 2.5 mM triethanolamine containing protease inhibitors and then lyophilized. Membrane and nuclei were removed with 0.05% NP-40 and 0.5% Triton X-100, respectively. Stress fibers were collected by centrifugation at 100,000 g for 1 h. The pellet (F-actin) and lyophilized soluble components (G-actin) were resuspended in 400 l Cytoskeletal buffer (0.5% Triton X-100, 50 mM NaCl, 20 mM HEPES, 1 mM EDTA). Equal volumes of the F and G fractions were separated by SDS-PAGE, and blots were probed with a pan-actin antibody then reprobed with antibodies to specific actin isoforms. Bands were visualized by enhanced chemiluminescence and quantified by densitometry using manual background subtraction.
Rac and Cdc42 activity. Contractile normoxic and hypoxic myocytes were stimulated with 10 Ϫ6 M U46619 or buffer for 30 min. Lysates collected in ice-cold lysis buffer (50 mM Tris, pH 7.5, 10 mM MgCl2, 0.5 M NaCl, 2% Igepal) containing protease inhibitors (in g/ml: 0.62 pepstatin A, 0.62 leupeptin, 140 benzamidine, 120 tosyl arginine methyl ester) were clarified by centrifugation at 10,000 revolution/min for 5 min in 4°C. Active Rac1 and Cdc42 were precipitated with glutathione S-transferase-tagged PAK-PAK-binding domain protein on colored agarose beads. Proteins were eluted by centrifugation and separated by SDS-PAGE. Blots were probed with anti-Rac1 or anti-Cdc42 monoclonal antibodies, and GTP-bound proteins were compared with their abundance in whole cell lysates. His-tagged Rac1 and Cdc42 proteins were included in the blots to ensure antibody specificity. Addition of GTP-␥S (200 M) was used as a positive control, and excess guanosine diphosphate (10 mM) as a negative control.
Activation of PAK and PI3K. Contractile normoxic and hypoxic myocytes were challenged for 30 min with 10 Ϫ6 M U46619 or diluent. Whole cell lysates were collected in ice-cold lysis buffer as above, and proteins were separated by 12% SDS-PAGE. Proteins were transferred onto nitrocellulose membranes and then blocked in Tris-buffered saline-Tween solution containing 5% milk. To determine PAK activation, blots were probed for phospho-PAK, stripped, and reprobed for total PAK protein abundance. Similarly, phosphatidylinositide-3-kinase (PI3K) activation state was assessed using antibody to phospho-Akt and then reprobed for total Akt.
Cdc42 association with N-WASp. Contractile normoxic and hypoxic myocytes were stimulated for 30 min with 10 Ϫ6 M U46619 or diluent and then lysed. Whole cell lysates (400 g) were precleared with 50% slurry of protein A Sepharose beads (GE Healthcare) and centrifuged at 16,000 g for 5 min. The precleared lysates were incubated overnight with 2 g N-WASp at 4°C. The precipitate was pulled down with 50% bead slurry before beads were washed in lysis buffer. Beads were boiled in 1ϫ Laemmli loading buffer, and eluted proteins were separated by SDS-PAGE. Blots were probed with anti-Cdc42 antibody, stripped, and reprobed with N-WASp to confirm equal sample loading. Protein bands were visualized by enhanced chemiluminescence (Amersham) and quantified under nonsaturating conditions by densitometry.
Force myography. Pulmonary arteries (600 -700 m diameter) from newborn (Ͻ24 h old), PPHN, or age-matched 3-day-old control piglets were mounted on a multichamber wire myograph (Danish Myo Systems) in oxygenated (95% O2-5% CO2) Ca 2ϩ Krebs-Henseleit buffer (in mM: 112.6 NaCl, 25 NaHCO3, 1.38 NaH2PO4, 4.7 KCl, 2.46 MgSO4, 1.91 CaCl2, 5.56 dextrose) at 37°C. Vessels were equilibrated at optimal length, determined from a length/tension curve deriving maximum active tension to high KCl Krebs (in mM: 50 KCl, 73.1 NaCl, 25 NaHCO 3, 1.38 NaH2PO4, 2.46 MgSO4, 5.56 dextrose, 2.5 CaCl2) before isometric contraction to 10 Ϫ6 M U46619. Newborn pulmonary arteries were incubated with serial concentrations of jasplakinolide and cytochalasin D during maximal U46619 contraction to determine effect of actin stabilization or destabilization on force development. Reversibility of actin agents was tested by repeat challenge with KCl and U46619. PPHN and control pulmonary arteries similarly equilibrated at optimal length were challenged with 10 Ϫ6 M U46619 in presence of 10 Ϫ5 M Y27632 (inhibiting Rho kinase), 100 M NSC23766 (inhibiting Rac), or 10 M IPA-3 (inhibiting PAK) for a minimum of 30 min. All force measurements were normalized to maximal contractile response to KCl. Vessels were then fixed in situ at rest or at maximum contraction (steady state, 5 min post-U46619 challenge) with 10% formalin, embedded in optimal cutting temperature compound in an end-on orientation, sectioned, and stained for quantification by laser-scanning cytometry (described below).
Laser-scanning cytometry for F/G-actin ratio in cells and tissues.
Serum-deprived myocytes were treated for the 3 days of normoxic or hypoxic exposure with 100 M NSC23766 (Rac1 inhibitor), 10 M IPA-3 (PAK1 inhibitor), or diluent and then challenged with 10 Ϫ6 M U46619 or diluent for 30 min before 3% paraformaldehyde fixation. Cells were permeabilized with 0.3% Triton X-100, rinsed, and stored in cyto-TBS buffer (200 mM Tris base, 1.54 M NaCl, 20 mM EGTA, 20 mM MgCl 2). Myocytes and pulmonary arteries fixed in situ on the myography were costained with Alexa-Fluor Phalloidin 633 (red, F-actin) and DNase 488 (green, G-actin), and nuclei were counterstained with Hoechst 33342. Cryosections (12 m) were also stained with anti-phospho-MLC, anti-␣-smooth muscle actin, anti-␥-actin, or anti-phospho-PAK for 1 h at room temperature and then washed in cyto-TBS ϩ 0.5 M NaCl and stained with FITC (green) and Cy5 (red); nuclei were counterstained with Hoechst 33342. Laser-scanning cytometry was used to quantify fluorescence integral intensity of red and green per cell, as previously described (13) . Briefly, cells were scanned at ϫ40 magnification under standardized settings of voltage, gain, and offset. Single myocyte nuclei or, in the case of tissue sections, cells within the arterial muscular layer, were identified by a primary contour gated to include nonoverlapping nuclei. Fixed-dimension peripheral contours were then defined at one pixel and seven pixels outside each primary contour, to include the sarcoplasm and exclude background; integral intensity of red and green was calculated for the area between these peripheral contours (37) . Actin polymerization (as the proportion of cellular actin incorporated into filaments) was defined as F/G-actin ratio per cell.
Data analysis. Data analyses used PRISM 5.0 (GraphPad Software). Comparisons were made between normoxic vs. hypoxic myocytes and between agonist-naïve vs. U46619-challenged cells by two-way ANOVA with post hoc Bonferroni correction. All values are expressed as means Ϯ SE, with P Ͻ 0.05 considered significant.
RESULTS
For all comparisons, normoxic and hypoxic control groups are abbreviated as NC (open bars) and HC (closed bars), respectively, whereas normoxic and hypoxic myocytes challenged with the TP agonist U46619 are abbreviated as NT (open hatched bars) and HT (closed hatched bars), respectively. The Rac and Cdc42 signaling pathways studied here are illustrated in Fig. 1 .
Actin isoforms. Actin filaments (F-actin) were isolated and compared with soluble (G-actin) components to determine the individual effects of hypoxia and thromboxane challenge on actin polymerization. Total actin and major actin isoforms separated into their filamentous and soluble components were quantified by immunoblot (Fig. 2) . We hypothesized that actin polymerization would be increased in hypoxic myocytes, in particular that of ␥-actin. Exposure to 72-h hypoxia (HC) resulted in increased actin in the filamentous fraction compared with NC, comprising a modest increase in ␣-actin and larger increase in ␥-actin polymerization. Stimulating normoxic and hypoxic cells with TP agonist U46619 increased polymerization of all three actin isoforms, but, whereas normoxic myocytes (NT) predominantly polymerized ␣-actin after agonist challenge, in hypoxic myocytes challenged with U46619 (HT), the largest component of filamentous actin was ␥-actin.
Active Rac and Cdc42. We investigated the activation state of Rho GTPases Rac and Cdc42 in hypoxia and following TP receptor signaling, hypothesizing agonist-induced activation of Cdc42 in vascular myocytes as demonstrated elsewhere in trachealis (48) . Active (GTP-bound) Rac and Cdc42 were isolated by affinity precipitation and normalized to total lysate protein content. Hypoxia downregulates Rac activity (Fig. 3A) while increasing Cdc42 activity (Fig. 3B) . TP receptor stimulation increased active Rac content in hypoxic cells only and further increased active Cdc42 in hypoxic myocytes.
PAK activation. We then measured phosphorylation of PAK, a serine/threonine protein kinase acting as downstream effector of activated Rac/Cdc42 regulating the organization of actin filaments (9) , to determine the cumulative burden of Rac and Cdc42 signaling. Hypoxia for 72 h increased phosphorylation of PAK. After U46619 challenge, phospho-PAK abundance increased to the level seen in untreated hypoxic myocytes but was not further elevated (Fig. 4) .
Cdc42 associated with N-WASp. Association of Cdc42 with N-WASp was measured by coimmunoprecipitation. N-WASp stimulates actin-nucleating activity of the Arp2/3 complex via interaction with active Cdc42(39) but not Rac. We hypothesized that Cdc42 activation would correspond with increased association with n-WASp. Hypoxic myocytes had less Cdc42 associated with N-WASp (Fig. 5) . Stimulating the TP receptor with U46619 increased association of Cdc42 with N-WASp in hypoxic cells only.
PI3K activation. To test whether observed changes in Rac and Cdc42 activity were regulated by increased upstream PI3K activity (11, 55) , we measured phosphorylation of Akt, a direct substrate of PI3K. Hypoxia decreased phospho-Akt levels in pulmonary artery myocytes (Fig. 6) . Stimulating the TP receptor with U46619 further decreased phospho-Akt in normoxic and hypoxic myocytes.
Effects of Rac and PAK inhibition on polymerization of actin isoforms.
To determine effects of PAK and Rac signals on actin polymerization, cultured myocytes were pretreated with NSC23766 (inactivates Rac) or IPA-3 (inhibits PAK). We first tested low and high doses of NSC23766 (50 and 100 M) and IPA-3 (10 and 30 M) to select the most effective concentrations (data not shown). Only high-dose NSC23766 decreased GTP-bound Rac, whereas both IPA-3 doses decreased phos- phorylation of PAK in pulmonary artery myocytes. Because PAK is a downstream effector of activated Rac, effects of NSC23766 on phospho-PAK were also measured (not shown). Inhibition of Rac had no effect on phospho-PAK levels in normoxic cells but decreased PAK activity in hypoxic PA myocytes. Effects of Rac and PAK inhibition on actin polymerization were measured by F-and G-actin staining (quantified ratiometrically by laser-scanning cytometry) of intact cells and also by immunoblot of cytoskeletal (F-actin) vs. cytosolic (G-actin) fractions from agonist-naïve myocytes. In normoxic PA myocytes, Rac inhibition had no effect on polymerization of actin, whereas PAK inhibition decreased actin polymerization. Hypoxia-induced polymerization of actin was sensitive to inhibition of either Rac or PAK (Fig. 7) , as was actin polymerization following U46619 stimulation of normoxic or hypoxic cells.
We then studied the effect of Rac and PAK signaling on polymerization of specific actin isoforms. In normoxic cells, ␣-actin polymerization required PAK activity, whereas inhibition of Rac depolymerized ␥-actin filaments. In hypoxic myocytes, polymerization of both ␣-and ␥-actin filaments is more sensitive to Rac inhibition, whereas PAK inhibition decreased polymerized ␥-actin (Fig. 8) . F/G-actin ratios determined by immunoblot (anti-actin) of fractionated cytoskeletal components from agonist-naïve myocytes were comparable to the corresponding laser-scanning cytometry findings.
Actin dynamics and contraction. We studied effects of actin-stabilizer and -destabilizer agents on polymerization of specific actin isoforms and by this approach the contribution of actin isoforms to contraction. We hypothesized that ␥-actin contributes to contractile force and thus that the polymerized ␥-actin may be considered a thin filament element, rather than a component of the internal resistor. Cytoskeletal and cytosolic fractions were collected; actin polymerization was quantified by immunoblot. Contraction of whole pulmonary artery was measured by vascular myography, following actin stabilization or destabilization. As described above, hypoxic exposure for 72 h increased actin polymerization ( Fig. 9A; anti-actin) , with increased polymerization of ␣-and ␥-actin isoforms. Stabilizing actin filaments with jasplakinolide had the greatest effect on increasing polymerization of ␥-actin. Destabilizing actin filaments with cytochalasin D equally depolymerized all three actin isoforms (Fig. 9A) . Finally, we studied the contributions of actin polymerization to vascular contraction. The effect of actin polymerization on U46619-induced force generation was measured by isometric wire myography in resistance pulmonary arteries from day 0 piglets (Fig. 9B) . Pulmonary arteries contracted to 10 Ϫ6 M U46619 and remained contracted over the course of the experiment until washout. Addition of jasplakinolide (at increasing doses Ն100 nM) elevated U46619-induced contractile force, whereas U46619-induced force decreased stepwise to increasing doses of cytochalasin D (Ն200 nM). The effects of jasplakinolide and cytochalasin D were promptly reversible upon washout and subsequent KCl and U46619 challenge (not shown). 
Effect of Rho kinase, Rac, and PAK inhibition on actin isoform polymerization.
To determine the effects of Rho kinase, Rac, and PAK signals on actin isoform polymerization, pulmonary arteries from 3-day-old PPHN animals and agematched NC were pretreated with Y27632 (inhibits Rho kinase), NSC23766 (inactivates Rac), or IPA-3 (inhibits PAK) before contraction with 10 Ϫ6 M U46619. Arteries fixed after 5-min contraction or relaxation while on the myograph at optimal length were sectioned and stained to quantify fluorescence integral intensity by laser-scanning cytometry. We hypothesized that PAK inhibition (reflecting loss of Cdc42 activity) would decrease vascular actin polymerization and thus contractile force in PPHN arteries. PAK inhibition by IPA-3 was confirmed by immunostaining for phospho-PAK (Fig.  10A) . Pulmonary arteries from hypoxic PPHN animals had increased polymerized actin. Challenge with thromboxane mimetic U46619 further increased the F/G-actin ratio in vessels from PPHN and control animals (Fig. 10B) , with the greatest actin polymerization in agonist-challenged PPHN arteries. We then assayed the effect of key pathway intermediates by pharmacological inhibition. Only Rac inhibition decreased the F/G-actin ratio in control arteries, whereas inhibiting Rho kinase, Rac, and PAK all led to decreased actin polymerization in PPHN pulmonary arteries (Fig. 10B) . Total immunostaining for both ␣-and ␥-isoforms of actin increased in the medial layer of PPHN arteries (Fig. 10, C and D) . In both control and PPHN arteries, only ␥-actin staining increased after U46619-mediated contraction. In control pulmonary arteries, inhibition of neither Rho kinase, Rac, or PAK had any effect on ␣-actin staining (Fig. 10C) ; however, in PPHN arteries, Rho kinase inhibition decreased ␣-and ␥-actin staining, whereas PAK inhibition decreased only ␥-actin staining (Fig. 10D) . To determine whether the increase in actin polymerization corresponded with increased contractile force, pulmonary arteries from normoxic and hypoxic animals were challenged with U46619 and force normalized to maximal KCl-mediated contraction. PPHN pulmonary arteries had markedly augmented contractile force to U46619 compared with control arteries (Fig. 10E) . Inhibiting Rho kinase slightly decreased U46619-induced contraction in control arteries while normalizing contractile force in PPHN vessels. Rac inhibition had no effect on contractile force in either group. Inhibiting PAK augmented U46619-induced contraction in PPHN. To clarify this finding, the effect of these inhibitors on smooth muscle calcium sensitivity was studied by immunostaining contracted and relaxed vessels for phosphorylation of the regulatory subunit of MLC. PPHN pulmonary arteries had increased phospho-MLC compared with control arteries (Fig. 10F) . MLC phosphorylation was further increased in all arteries contracted with U46619. Rac inhibition had no effect on phosphorylation of MLC. Preincubation with Y27632 significantly decreased phospho-MLC in all pulmonary arteries. In contrast, PAK inhibition significantly increased phospho-MLC in PPHN arteries challenged with U46619. These results correlated better with contractile force than did actin polymerization.
DISCUSSION
Adaptation to extrauterine life entails functional and structural remodeling of the pulmonary vasculature (3), initially
F/G actin ratio Fig. 7 . Effects of Rac and PAK inhibition on actin polymerization in hypoxic and U46619-challenged PA myocytes. Normoxic and hypoxic PA myocytes were preincubated for 3 days in media with 100 M NSC23766 (Rac inhibitor), 10 M IPA-3 (PAK inhibitor), or diluent and then challenged with TP agonist 10 Ϫ6 M U46619 or diluent for 30 min before paraformaldehyde fixation. Myocytes were stained with Phalloidin-633 (F-actin) and DNase-488 (G-actin). Nuclei were counterstained with Hoechst 33342 to illuminate a primary contour for quantification of F-and G-actin integral intensity per cell. Actin polymerization expressed as F/G-actin ratio (*P Ͻ 0.001 vs. NC; ·P Ͻ 0.001 vs. U46619-naïve control group; #P Ͻ 0.001 vs. untreated group; n ϭ 3 independent experiments). Normoxic and hypoxic PA myocytes were preincubated for 3 days in media with 100 M NSC23766 (Rac inhibitor), 10 M IPA-3 (PAK inhibitor), or diluent before stress fiber isolation. F-actin was isolated from G-actin; fractions were separated by SDS-PAGE to quantify F/G-actin ratio using pan-actin (anti-actin), ␣-, ␤-, and ␥-actin antibodies (***P Ͻ 0.001 vs. untreated NC; ·P Ͻ 0.05, ··P Ͻ 0.01 and ···P Ͻ 0.001 vs. untreated control group; n ϭ 3 independent experiments).
achieved by increasing the length and surface-to-volume ratio of PASMCs, expanding lumen diameter, and lowering vascular resistance (21) . These changes in myocyte architecture are attributed to rapid depolymerization and remodeling of cytoskeletal and contractile filaments (1) . Therefore, dynamic polymerization and depolymerization of vascular smooth muscle actin filaments is required for adequate postnatal pulmonary artery blood flow. Histologically, neonatal pulmonary hypertension is characterized by persistently elevated actin content, in particular ␥-actin (20) . In hypoxia, actin polymerization is further increased by the presence of circulating vasoconstrictors such as thromboxane (13) . It is established that disturbing actin dynamics decreases contractile force (31) or velocity of contraction (30) . However, the regulation and importance of increased agonist-induced actin polymerization in hypoxic pulmonary arterial smooth muscle during the perinatal period are undefined. We previously reported polymerization of actin in hypoxic neonatal pulmonary arteries associated with increased force of U46619-mediated contraction in a direct relationship that we did not observe in systemic arteries. In that study, hypoxia promoted filamentous actin accumulation and enhanced U46619-mediated vasoconstriction in neonatal pulmonary arteries via Rho-linked pathways, but thromboxane-induced actin polymerization was RhoA independent (13) . To this understanding, we add the following conclusions from the present study: 1) hypoxia downregulates Rac pathway activity while upregulating the Cdc42 pathway in contractile PA myocytes; 2) challenging hypoxic PA myocytes with thromboxane mimetic U46619 activates both the Rac and Cdc42 signaling pathways; 3) Rac and Cdc42 are independent of PI3K activity in agonist-naïve and agonist-stimulated hypoxic PA myocytes; 4) hypoxia increases PAK phosphorylation via Cdc42, but PAK activity is unaltered after thromboxane receptor stimulation, as U46619 increases association of Cdc42 with N-WASp; 5) in normoxic cells, actin polymerization is independent of Rac, but ␣-actin filament content is sensitive to inhibition of PAK; 6) inhibition of either Rac or PAK prevents hypoxiainduced actin polymerization, and Rac inhibition prevents polymerization of ␣-and ␥-actin filaments, whereas PAK inhibition only prevents polymerization of ␥-actin filaments; 7) ␣-and ␥-actin isoforms both contribute to the increased filamentous actin seen in hypoxia, but in hypoxic myocytes the primary filamentous actin isoform switches from ␣ to ␥, in a timeframe correlating with the time course of increased agonist-mediated contraction; 8) ␥-actin contributes to U46619-mediated force, as determined by selective filament stabilization; 9) actin polymerization in PPHN pulmonary arteries is increased and further increases following agonist challenge, comprising primarily ␥-actin; and 10) actin polymerization in PPHN vessels contracted with U46619 owes to PAK but not Rac (thus involves Cdc42) and to Rho signaling, but comparative effects on force cannot be determined because of the overwhelming effect of inhibitor compounds on calcium sensitivity of contraction. Monomeric actin (globular or G-actin) polymerizes in a head-to-tail fashion to form helical thin filaments (54) . Most cells maintain a large intracellular G-actin pool, which allows them to rapidly reorganize their cytoskeleton when subjected to environmental stressors; in vascular smooth muscle, 30 -40% of total actin is monomeric for spontaneous polymerization into filaments (7). Actin polymerization leads to increased Fig. 9 . Effects of actin stabilization or destabilization on actin isoform polymerization in PA myocytes. A: normoxic and hypoxic PA myocytes were treated with 1 M jasplakinolide, 2 M cytochalasin D, or diluent for 30 min before stress fiber isolation. F-actin was isolated from G-actin and separated by SDS-PAGE; F/G-actin ratio was quantified using pan-actin (anti-actin), ␣-, ␤-, and ␥-actin antibodies. B: isometric contractions to 10 Ϫ6 M U46619 in day 0 resistance pulmonary arteries, followed by addition of increasing doses of jasplakinolide (50, 100, 200, 500, and 1,000 nM) and cytochalasin D (100, 200, 400, 500, and 2,000 nM) (**P Ͻ 0.01 vs. NC, open bar; ··P Ͻ 0.01 and ···P Ͻ 0.001 vs. untreated control; n ϭ 3 independent experiments).
force generation and contraction (7, 35, 44) . The G-actin pool and the stability of F-actin are controlled by actin-binding proteins that sever filaments to create new nucleation sites (38) , cap or uncap existing filaments (8) , sequester proteins to control the rate of polymerization and depolymerization (53) , and realign existing filaments to control cell stiffness (29) . Small changes in the F/G-actin pool in smooth muscle cells confer large increases in contraction (57) .
Mechanistically, the Rho family of p21 small GTP-binding proteins regulates actin cytoskeleton dynamics. RhoA, Rac, and Cdc42 are well characterized Rho GTPases, functioning as molecular switches and, when GTP-bound, interacting with effector molecules (45) to induce formation of stress fibers, lamellipodia, and filopodia (19) . RhoA functions involve reorganizing preexisting actin filaments, whereas Rac and Cdc42 promote newly polymerized actin by uncapping or severing Ϫ6 M U46619 (E). Arteries were fixed in situ on the myograph (5 min post-U46619 challenge) and then stained for phospho-PAK1 (A), Phalloidin-633 (F-actin) and DNase-488 (G-actin) (B), ␣-actin (C), ␥-actin (D), and phospho-MLC (F). Nuclei were counterstained with Hoechst 33342 to illuminate a primary contour for quantification of red and green integral intensity per cell. Actin polymerization expressed as F/G-actin ratio (***P Ͻ 0.001 vs. D3N; ·P Ͻ 0.001 vs. corresponding U46619-naïve group; #P Ͻ 0.001 vs. untreated D3N U46619 or D3H U46619 group; n ϭ 3 independent experiments).
existing filaments or stimulating de novo actin nucleation (28) . PI3K is capable of contributing to Rho GTPase activation; however, phosphorylation of a common PI3K target appears downregulated in our hypoxic model and further decreases with U46619 exposure. We therefore focused on direct Rho GTPase activation by hypoxia and/or by thromboxane agonist. Numerous studies demonstrate cross-talk and a hierarchy among Rho GTPases, indicating antagonizing activity between Rac and RhoA (40, 56, 58) but also coactivation of Rac and Cdc42 in lamellipodia and membrane ruffles (26, 51) . In fibroblasts, Cdc42 activates Rac, which in turn activates RhoA (33) . A similar Rac-Rho and Cdc42-Rac hierarchical pathway occurs in our model. We previously reported increased RhoA activity after 72-h hypoxia but unchanged RhoA activity after a U46619 challenge (13) . In the present study, hypoxia decreases Rac activity while upregulating Cdc42 activity. Hypoxic myocytes challenged with U46619 increased active Rac and further increased GTP-bound Cdc42.
A common downstream effector of Rac and Cdc42 is the protein (PAK), which converges with the RhoA pathway by activating LIMK. Phosphorylation of Ser3 on cofilin by LIMK (downstream of both RhoA and Rac1) promotes F-actin stability and elongation (43) . To dissect this complex pathway, we used a multiple-inhibitor-based approach. Effects uncovered attributable to inhibition of PAK, but not found upon inhibition of Rac, were taken to represent Cdc42 signaling via PAK. We find that hypoxia increases phosphorylation of PAK via Cdc42, but phospho-PAK is not altered after the TP receptor is stimulated with U46619. However, N-WASp association with Cdc42 is increased by U46619. We conclude that, because of divergent signaling, U46619 challenge triggers a Cdc42 signal to N-WASp without initiating PAK activation. Cdc42 signaling to WASp has been implicated in both actin polymerization and force development following contractile agonist stimulation (48) . WASp family proteins activate Arp2/3-mediated F-actin branching, leading to rapid polymerization of actin by increasing the number of free barbed ends (25) . These proteins are thought to primarily promote endocytosis, as N-WASp accelerates actin polymerization near invaginating clathrincoated pits, promoting endosome formation. We speculate that newly polymerized actin after thromboxane challenge may also be important for TP receptor endocytosis because we observe increased internalization of the hypoxic TP receptor exposed to U46619 (13a).
The major actin isoforms differ in their NH 2 -terminal sequences: ␣ (skeletal, cardiac, and smooth muscle variants), ␤, and ␥. Large arteries contain ϳ60% ␣-smooth muscle actin, 20% ␤-actin, and 20% ␥-actin (12) . Importantly, the only reported histological marker of altered pulmonary arterial cytoskeletal architecture during normal postnatal transition is the rapid loss of ␣-and ␥-actin immunostaining; in PPHN, this does not occur (20) . We also report increased ␣-and ␥-actin abundance in cytoskeletal fractions following in vitro hypoxia and in neonatal PPHN vessels after hypoxia in vivo compared with NC. We find that the further increase in agonist-induced actin polymerization following thromboxane challenge of hypoxic myocytes consists largely of filamentous ␥-actin. Other reports also suggest that agonist-induced incorporation of actin into cortical filaments of vascular smooth muscle (24) comprises primarily ␥-actin(23). ␣-Actin predominates in tonically contractile vascular smooth muscle, whereas ␥-actin prevails in phasically contractile gastrointestinal smooth muscle (50) ; this may hold a key to their differing roles in contraction. ␥-Actin expression may be developmentally regulated; in late pregnancy, ␥-actin expression increases in uterine myocytes and may facilitate myometrial contraction (42) . That ␥-actin promotes force development is supported by the observation that overexpression of cytoplasmic ␥-actin in thin filaments prevents loss of force during eccentric contraction of dystrophic skeletal muscle (2) . In contractile aortic myocytes, adrenergic contraction results in a net polymerization of ␥-actin, which contributes toward agonist-induced tone without affecting KCl-mediated contraction (23) . The importance of increased ␥-actin for PPHN vasoconstriction has not been clarified. In this study, we partly attribute increased agonist-induced contractile force to ␥-actin polymerization on the basis of stress fiber isolation from hypoxic myocytes and on increased isometric force of U46619-mediated contraction in presence of jasplakinolide, an agent that in our hands proves relatively selective for its stabilization of filamentous ␥-actin.
Finally, we sought to verify the pathway for signaling to actin isoform polymerization following in vitro hypoxia and in hypoxic PPHN tissues. In agonist-naïve myocytes, hypoxiainduced ␣-actin polymerization is Rac sensitive, whereas ␥-actin polymerization demonstrates sensitivity to both Rac and PAK inhibition. In hypoxic PPHN arteries, total ␣-actin immunostaining is increased, but there is little change with thromboxane challenge; Rho kinase, Rac, and PAK inhibitors also have no discernible effect. Total ␥-actin staining increases in hypoxic pulmonary artery and increases further with agonist challenge; this is sensitive to Rho inhibition and to PAK but not Rac inhibition, implicating Cdc42 signaling. The filamentous-to-globular actin ratio increases significantly in hypoxic PPHN and increases further after a thromboxane challenge; this is most sensitive to inhibition of Rac or PAK (which increase globular actin to normoxic levels). These findings fall in accord with our in vitro data. Although Rho kinase inhibition also decreased total actin polymerization, this effect was modest compared with that of PAK or Rac inhibition and was not different between hypoxic and normoxic arteries. We conclude that, although both Rho and PAK inhibition alter filamentous actin composition, in hypoxic pulmonary artery, Cdc42 (via PAK) has greater direct impact on agonist-induced actin polymerization. Regarding specificity of inhibitors, direct PAK inhibition decreases phospho-PAK; Rac inhibition has a lesser effect on phospho-PAK, as PAK would still receive the uninhibited Cdc42 signal. When studying the effects of the pathway inhibitors on force development in pulmonary arteries, we saw the expected increase in U46619-induced contractile force in PPHN vessels compared with age-matched NC. However, both the Rho kinase inhibitor (32) and PAK inhibitor (6) have major off-target effects on calcium sensitization, appreciable here after PAK inhibition as increased MLC phosphorylation resulting in increased force, despite significant depolymerization of actin following PAK inhibition. Although we conclude that polymerization of actin is indeed sensitive to PAK inhibition, measured force of contraction reflects more the phosphorylation of MLC, and therefore the effect of actin polymerization on contractile force cannot be further interpreted from the ex vivo preparation.
Actin isoforms segregate into filament classes and have distinct localization patterns (14, 34) . Both ␣-and ␥-actin exist within contractile thin filaments, whereas the cytoskeletal filaments, thought to help maintain cell shape, contain nonmuscle ␤-and cytoplasmic ␥-actin isoforms. It is arguable that actin polymerized in response to chemical or mechanical signals is located submembranously and functions to transmit force to the sarcolemma (17) by strengthening connections between adhesion junctions and actin filaments (57) . In this study, we measured filamentous and globular actin pools by laser-scanning cytometry and by isolation of stress fibers. Using the latter method, we can determine isoform composition of polymerized actin in response to hypoxia and to a thromboxane challenge; however, we cannot comment on series vs. parallel orientation of these actin filaments. Additionally, ␥-actin quantified in stress fibers cannot be further separated into smooth muscle or non-muscle isoforms using 2-D gels. Where filamentous and globular actin are quantified using laser-scanning cytometry, the subcellular location of newly polymerized ␣-and ␥-actin was not determined.
We conclude that hypoxic pulmonary artery myocytes exposed to thromboxane polymerize actin, owing in large part to Cdc42 pathway activity. Thromboxane challenge of hypoxic pulmonary artery induces polymerization of ␣ and ␥-actin isoforms, contributing in part toward thromboxane-mediated vasoconstriction in PPHN. Although elements of the actin polymerization pathway could theoretically be selectively targeted to alleviate the contracture of PASMC architecture in early PPHN, screening of potential downstream targets would be advisable to avoid unintentional calcium sensitization. 
